
Sono stati resi noti i Late-Breaking Clinical Trials che verranno presentati nel corso delle Hot Line Sessions di ESC 2022, il prossimo Congresso dell’European Society of Cardiology in programma dal 26 al 29 agosto 2022 a Barcellona. Come sempre la redazione di Cardioinfo sarà presente al Congresso per interviste, news e approfondimenti.
“Abbiamo creato un programma Hot Lines davvero eccezionale per il Congresso ESC 2022 – ha commentato Stephen Windecker, chairman nel comitato scientifico dell’evento – e incoraggio tutti a esplorarli. I risultati di questi importanti studi clinici hanno il potenziale per migliorare gli outcome dei pazienti, avere un impatto sulla pratica clinica e informare le future linee guida”. Di seguito la lista degli studi, divisi per giornata congressuale:
Venerdì 26 agosto:
HOT LINE SESSION 1:
- TIME – The Treatment in Morning versus Evening study.
- A polypill strategy in secondary prevention: results of the SECURE trial
- PERSPECTIVE – Sacubitril/valsartan and cognitive function in HFmrEF and HFpEF
Sabato 27 agosto:
HOT LINE SESSION 2:
- DANCAVAS – Screening and intervention to prevent cardiovascular disease.
- ADVOR – Acetazolamide in acute heart failure.
- DANFLU-1 – High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults.
- BOX – Oxygen therapy in comatose OHCA patients.
- BOX – Optimizin blood pressure in post-resuscitation care.
HOT LINE SESSION 3:
- REVIVED – Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction.
- ALL-HEART – Allopurinol and cardiovascular outcomes in ischaemic heart disease.
- EchoNet-RCT – Safety and Efficacy Study of AI LVEF.
HOT LINE SESSION 4:
- DELIVER – Dapagliflozin in Heart Failure with Mildly Reduced and Preserved Ejection Fraction.
- Pooled analysis of DAPA-HF and DELIVER.
- A Pre-Specified Meta-Analysis of DELIVER and EMPEROR-Preserved.
Domenica 28 agosto:
HOT LINE SESSION 5:
- INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation.
- PACIFIC-AMI – Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction.
- PACIFIC-STROKE – Phase 2 Program of AntiCoagulation via Inhibition of FXIa by the oral Compound BAY 2433334 – non-cardioembolic STROKE study.
- AXIOMATIC-SSP: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
HOT LINE SESSION 6:
- eBRAVE-AF – Smartphone-based AF screening.
- Causal AI substantially improves the validity of estimating cardiovascular risk and benefit.
- AI-ENHANCED detection of Aortic Stenosis.
HOT LINE SESSION 7:
- DanNICAD-2 – Perfusion scanning with MR or PET after a positive CT coronary angiography.
- The PRE18FFIR trial: Coronary Plaque Activity to Predict Recurrent Events.
- The FRAME-AMI trial.
Lunedì 29 agosto:
HOT LINE SESSION 8:
- ISCHEMIA-CKD EXTEND – Clinical Outcomes at 5 years of Follow-up.
- 15-month results of the MASTER DAPT trial.
- FOURIER-OLE: Primary Results.
- FIDELITY: Causes of mortality.
- PARADISE-MI trial – Win Ratio Analysis.
HOT LINE SESSION 9:
- CTT meta-analysis of the effects of statins on muscle symptoms.
- MTT – Assessing the effects of ARBs and beta-blockers in Marfan Syndrome.
- PANTHER – P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease.
- RTC – Radial versus femoral access for coronary procedures.
HOT LINE SESSION 10:
- COVID-PACT – Antithrombotic therapy in critically Ill COVID-19 patients.
- ACT Outpatient trial.
- ACT Inpatient trial.